Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc (ACAD) is a Healthcare stock tracked by StreetAlpha. It last closed at $20.40 on Sep 28. ACAD reports earnings on Wed, Nov 4, 2026. The average 12-month price target from 11 analysts is $33.00 (+61.8% from the last close), with a high of $49.00 and a low of $25.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (9 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ACAD, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print totaling $530K, the largest $530K.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 11 analysts who set a price target on ACAD in the past 90 days. The average target is $33.00, with a high of $49.00 and a low of $25.00, compared with the last close of $20.40.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Deutsche Bank | Target lowered | Buy | $38 → $31 |
| Sep 25 | HC Wainwright & Co. | Maintained | Buy | $33 |
| Sep 25 | Citizens | Target lowered | Buy | $36 → $33 |
| Sep 25 | BMO Capital | Target lowered | Buy | $36 → $34 |
| Sep 25 | Needham | Target lowered | Buy | $41 → $35 |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACAD is in one of them and how their past ACAD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACAD in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.